N/A
N=110
Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)
Hepatitis C, Chronic · Hepacivirus
Bottom Line
View on ClinicalTrials.gov: NCT00705263 ↗Enrolled (actual)
110
Serious AEs
—
Results posted
Jul 2009
Primary outcome: Primary: Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use. — 104; 102; 102; 102 Satisfied Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Peginterferon alfa-2b (SCH 54031) (Biological); Ribavirin (SCH 18908) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Schering-Plough
- Primary completion
- May 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use. |
104; 102; 102; 102; 101; 101 | — |
Summary
The current gold standard for treatment of chronic hepatitis C is pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness. This is the idea behind the development and usage of the PegIntron pen (PegPen). Therefore, it is worthwhile to evaluate patients' satisfaction with this novel device. The results of the study will be used to improve PegPen training techniques for patients and health care providers.
Eligibility Criteria
Inclusion Criteria
- Patients with chronic hepatitis C treated with the PegIntron pen plus Rebetol
Exclusion Criteria
- Not willing to participate in the study
Data sourced from ClinicalTrials.gov (NCT00705263). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.